维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

18篇 您的检索式：作者名="Azad NS"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Demographic and Clinicopath- ologic features of membranous glomerulonephritis 显示文摘	Azad NS Muzaffar S Pervez S	2004	J CoU Physi- cians Surg Pak2004，14，1：	1
	2	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity显示文摘	Azad NS Posadas EM Kwitkowski VE		0，，22：	1
	3	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity显示文摘	Azad NS Posadas EM Kwitkowski VE	2008	J Clin Oncol2008，26，：	1
	4	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity 显示文摘	Azad NS Posadas EM Kwitkowski VE etal	2008	J Clin Oncol2008，26，22：	1
	5	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity显示文摘	Azad NS Posadas EM Kwitkowski VE	2008	J Clin Oncol2008，26，22：	1
	6	Keratoacanthomas assodated with sorafenib therapy 显示文摘	Kong HH Cowen EW Azad NS	2007	J Am Acad Dermatol2007，56，1：	1
	7	Proteomics in clinical trials and practice:present uses and future promise显示文摘	Azad NS Rasool N Annunziata CM	2006	Mol Cell Proteomics2006，5，：	1
	8	Uterine perivascular epithelioid cell tumour presenting as a cervical mass 显示文摘	Azad NS Aziz AB Pervez S	2006	J Pak Med Assoc2006，56，2：	1
	9	Proteomies in clinical trials and practice:present uses and future promise 显示文摘	Azad NS Rasool N Annunziata CM	2006	Mol Cell Proteomics2006，5，10：	1
	10	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity 显示文摘	Azad NS Posadas EM Kwitkowski VE	2008	J Clin Oncol2008，26，22：	1
	11	Thymoma: a clinicopathologic association of World Health Organization histologic subtype and invasire behaviour显示文摘	Azad NS Ahmad Z Ahsan A	2007	J Coil Physicians Surg Pak2007，17，11：	1
	12	The ongoing evolution ofproteomics in malignancy 显示文摘	Dhamoon AS Kohn EC Azad NS	2007	Drug Discov Today2007，12，1718：	1
	13	Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with mic- rosatellite unstable (MSI) tumors 显示文摘	DT Le NS Azad D Laheru	2014	J Clin Oncol2014，32，15：	1
	14	Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity 显示文摘	Azad NS Posadas EM Kwitkowski VE	2008	J Clin Oncol2008，26，22：	1
	15	Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy显示文摘	Azad NS Annunziata CM Steinberg SM	2008	Cancer2008，112，8：	1
	16	Hand-foot skin reactionincreases withcumulative sorafenib dose and with combination anti-vascaular endothelial growth factor therapy显示文摘	Azad NS Aragon-Ching JB Dahut WL	2009	Clin Cancer Res2009，15，：	1
	17	Long- term results of primary syndactyly correction by the trilobed flap technique 显示文摘	Niranjan NS Azad SM Fleming AN	2005	Br J Plast Surg2005，58，1：	1
	18	Hand-foot skin reaction increases with cumulative sorafenib dose and with combina- tion anti-vascular endothelial growth factor therapy显示文摘	Azad NS Aragon-Ching JB Dahut WL	2009	Clin Cancer Res2009，15，4：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费